低分子肝素联合孕期营养体重管理在妊娠期代谢综合征中的应用效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the application effect of Low Weight Molecular Heparin combined with pregnancy nutrition interference and weight management use in the treatment for gestational metabolic syndrome.Methods A total of 120 pregnant women with metabolic syndrome during pregnancy who were admitted to the Department of Obstetrics,Zhuzhou People′s Hospital Affiliated to Changsha Medical University from January 2017 to October 2019 were selected as the research subjects.They were divided into treatment group (60 cases) and control group (60 cases) by lotteries.The pregnant women in the control group received routine examination and management of high-risk pregnancy, and the pregnant women in the treatment group received Low Molecular Weight Heparin therapy and nutritional weight management during pregnancy from 24 to 28 weeks of gestation.Platelet, coagulation routine, D-dimer, blood lipid routine indexes and maternal and infant complications were compared between the two groups.Results There were no significant differences in platelet, prothrombin time (PT), D-dimer, triacylglycerol and high-density lipoprotein between the two groups before intervention (P>0.05).After intervention, platelet, PT, D-dimer and triglyceride in the treatment group were lower than those before intervention and lower than those in the control group, while high-density lipoprotein was higher than those before intervention and higher than those in the control group, the differences were statistically significant (P<0.05).The incidence of maternal complications of preeclampsia, cesarean section, postpartum hemorrhage, premature rupture of membranes and polyhydramnios in treatment group was lower than that in control group,the incidence of premature birth, neonatal asphyxia, macrosomia and low birth weight in the treatment group was lower than that in the control group, the differences were statistically significant (P<0.05).Conclusion Low Molecular Weight Heparin combined with nutritional weight management during pregnancy is effective for patients with metabolic syndrome during pregnancy.It can effectively prevent and cure pre-thrombosis, significantly reduce the blood lipid and the incidence of maternal and infant complications, and improve neonatal outcomes.

Key words： Gestational metabolic syndrome；Low molecular weight heparin；Pregnancy nutrition interference and weight management Maternal and infant complications Neonatal outcomes

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Hui
	HUANG Li
	LIANG Jun

Cite this article:

LI Hui,HUANG Li,LIANG Jun. Application effect of Low Weight Molecular Heparin combined with pregnancy nutrition interference and weight management use in the treatment for gestational metabolic syndrome[J]. 中国当代医药, 2021, 28(36): 101-104.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I36/101

[3]	吴琳琳，雷琼，段冬梅，等.妊娠期代谢综合征：一个值得探讨的科学问题[J].中国实用妇科与产科杂志，2018，39（9）：989-993.
[5]	王丽萍，赵倩，王鹂麟，等.孕期营养干预和代谢性危险因素对妊娠结局的影响[J].中国循证儿科杂志，2013，8（6）：425-431.
[6]	麦彩园，段冬梅，牛建民，等.脂蛋白相关磷脂酶A2 与妊娠期糖尿病患者产后糖代谢异常的相关性[J].中华糖尿病杂志，2014，6（9）：645-649.
[10]	雷琼，牛建民，段冬梅，等.妊娠中期脂代谢异常与不良妊娠结局的相关性[J].中华围产医学杂志，2014，8：527-530.
[11]	牛建民，雷琼，吕莉娟，等.妊娠期代谢综合征诊断标准的评价及危险因素分析[J].中华妇产科杂志，2013，48（2）：92-97.
[12]	谢幸，孔北华，段涛，等.妇产科学[M].9 版.北京：人民卫生出版社，2018：108.
[1]	Lorenzo C，Williams K，Hunt KJ，et al.The National Cholesterol Education Program—Adult Treatment Panel Ⅲ.International Diabetes Federation，and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes[J].Diabetes Care.2007，30：8-13.
[2]	Lei Q，Niu J，Lv L，et al.Clustering of metabolic risk factors and adverse pregnancy outcomes：a prospective cohort study[J].Diabetes Metab Res Rev，2016，32（8）：835-842.
[4]	Galanaud JP，Laroche JP，Righini M.The history and historical treatments of deep vein thrombosis[J].J Thromb Haemost，2013，11（3）：402-411.
[7]	Mai C，Wang B，Wen J，et al.Lipoprotein-associated phospholi pase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus[J].Gynecol Endocrinol，2014，30（3）：241-244.
[8]	Whelton PK，Carey RM，Aronow WS，et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guide line for the Prevention，Detection，Evaluation，and Management of High Blood Pressure in Adults：Executive Summary：A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Hypertension，2018，71（6）：1269-1324.
[9]	APO Study Cooperative Research Group，Metzger BE，Lowe LP，et al.Hyperglycemia and adverse pregnancy outcomes[J].N Engl J Med，2008，358（19）：1991-2002.
[13]	Ageno W，Dentali F，Grandi AM.New evidence on the potential role of the metabolic syndrome as a risk factor for venous thrombo-embolism[J].J Thromb Heamost，2009，7（5）：736-738.
[14]	王喜红，金红.代谢综合征引起血栓性疾病的研究进展[J].医学综述，2011，17（5）：767-768.
[15]	Aguilar D，Goldhaber SZ.Clinical uses of low-molecularweight heparins[J].Chest，1999，115（5）：1418-1423.
[16]	Shomer E，Katzenell S，Zipori Y，et al.Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function[J].Thromb Res，2016，137：141-147.
[17]	Luley L，Schumacher A，Mulla MJ，et al.Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia[J].Am J Reprod Immunol，2015，73（5）：417-427.
[18]	颜明明，刘利月，戴婷婷，等.低分子肝素类药物的临床应用[J].中国医药指南，2018，16（18）：39-40.